IL312026A - Therapeutic rna for lung cancer - Google Patents

Therapeutic rna for lung cancer

Info

Publication number
IL312026A
IL312026A IL312026A IL31202624A IL312026A IL 312026 A IL312026 A IL 312026A IL 312026 A IL312026 A IL 312026A IL 31202624 A IL31202624 A IL 31202624A IL 312026 A IL312026 A IL 312026A
Authority
IL
Israel
Prior art keywords
lung cancer
therapeutic rna
rna
therapeutic
lung
Prior art date
Application number
IL312026A
Other languages
English (en)
Hebrew (he)
Inventor
Rold?N Diana Barea
Melanie Hein
Verena Kissler
Ugur Sahin
Ruprecht Kuner
Martin Suchan
Carina Walter
David Weber
Lena Mareen Kranz
Original Assignee
BioNTech SE
Tron – Translationale Onkologie An Der Universit?Tsmedizin Der Johannes Gutenberg Universit?T
Rold?N Diana Barea
Melanie Hein
Verena Kissler
Ugur Sahin
Ruprecht Kuner
Martin Suchan
Carina Walter
David Weber
Lena Mareen Kranz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2021/078022 external-priority patent/WO2023061550A1/en
Application filed by BioNTech SE, Tron – Translationale Onkologie An Der Universit?Tsmedizin Der Johannes Gutenberg Universit?T, Rold?N Diana Barea, Melanie Hein, Verena Kissler, Ugur Sahin, Ruprecht Kuner, Martin Suchan, Carina Walter, David Weber, Lena Mareen Kranz filed Critical BioNTech SE
Publication of IL312026A publication Critical patent/IL312026A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL312026A 2021-10-11 2022-10-10 Therapeutic rna for lung cancer IL312026A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2021/078022 WO2023061550A1 (en) 2021-10-11 2021-10-11 Therapeutic rna for lung cancer
EP2022050135 2022-01-05
PCT/EP2022/078084 WO2023061931A1 (en) 2021-10-11 2022-10-10 Therapeutic rna for lung cancer

Publications (1)

Publication Number Publication Date
IL312026A true IL312026A (en) 2024-06-01

Family

ID=84286153

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312026A IL312026A (en) 2021-10-11 2022-10-10 Therapeutic rna for lung cancer

Country Status (11)

Country Link
US (1) US20240415946A1 (https=)
EP (1) EP4415747A1 (https=)
JP (1) JP2024537298A (https=)
KR (1) KR20240099175A (https=)
AR (1) AR127317A1 (https=)
AU (1) AU2022365280A1 (https=)
CA (1) CA3234915A1 (https=)
IL (1) IL312026A (https=)
MX (1) MX2024004421A (https=)
TW (1) TW202333803A (https=)
WO (1) WO2023061931A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025201659A1 (en) * 2024-03-28 2025-10-02 BioNTech SE Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001231204A1 (en) * 2000-01-27 2001-08-07 Sidney Kimmel Cancer Center Genetically engineered tumor cell vaccines
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
US20180126003A1 (en) * 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
TW202134430A (zh) * 2019-12-03 2021-09-16 美商紐沃進公司 腫瘤細胞疫苗

Also Published As

Publication number Publication date
MX2024004421A (es) 2024-05-06
AR127317A1 (es) 2024-01-10
WO2023061931A1 (en) 2023-04-20
US20240415946A1 (en) 2024-12-19
JP2024537298A (ja) 2024-10-10
TW202333803A (zh) 2023-09-01
EP4415747A1 (en) 2024-08-21
AU2022365280A1 (en) 2024-05-02
KR20240099175A (ko) 2024-06-28
CA3234915A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
ZA202106392B (en) Therapeutic rna for prostate cancer
DK3768830T5 (da) Cancerterapi
EP4190173C0 (en) METABOLIC THERAPY FOR CANCER
IL287554A (en) Rana is therapeutic for ovarian cancer
EP4308121A4 (en) THERAPEUTIC CONJUGATES
IL312025A (en) Therapeutic rna for lung cancer
EP4463553C0 (en) ADVANCED RNA TARGETING (ARNATAR)
EP4440623A4 (en) Polytherapy for the treatment of cancer
EP3927328A4 (en) INHALABLE THERAPEUTIC AGENT
IL312249A (en) Combination therapy for treating lung cancer
EP4271392A4 (en) MATRIX-DIRECTED IMMUNOMODULATION FOR CANCER THERAPY
EP4122465A4 (en) THERAPEUTIC AGENT AGAINST BREAST CANCER
IL284646A (en) Therapeutic RNA for the treatment of solid cancer tumors in advanced stages
EP4103208A4 (en) RECOMBINANT THERAPEUTIC INTERVENTIONS FOR CANCER
EP4025203A4 (en) CANCER TREATMENT
IL312026A (en) Therapeutic rna for lung cancer
EP4401721A4 (en) CANCER TREATMENT
EP4356127A4 (en) THERAPEUTIC OLIGONUCLEOTIDE METHODS
EP4166147A4 (en) Sensitiser for cancer treatment
EP4188431A4 (en) Combination therapy for cancer
EP4135849C0 (en) MIV-818/LENVATINIB COMBINATION THERAPY FOR LIVER CANCER
IL286452A (en) Methods for the diagnosis of lung cancer
EP3777828A4 (en) PULMONARY SURFACTANT ANTI-CANCER DRUG
EP4309714A4 (en) Inhaler
HUE071223T2 (hu) Kombinációs terápia májbetegség kezelésére